Abstract
The industrial scale approach to biofluid analysis contrasts withthe high throughput approach (using human plasma as an example).
Keywords: industrial‐scale; plasma; serum; mass spectrometry; high throughput; bioinformatics
Industrialization of Proteomics: Scaling UpProteomics Processes
Keith Rose, GeneProt Inc., Ganeva, Switzerland
Published online: January 2006
DOI: 10.1038/npg.els.0006199
|
Figure 1.
Plasma protein concentrations. Graph showing a proposed log–log relationship between plasma protein concentration and number of proteins at the various concentrations. Some well‐known proteins are indicated at their normal plasma concentrations showing a known dynamic range spanning 12 orders of magnitude (albumin to tumor necrosis factor). The advantage of large sample size is indicated by the difference between the dotted line (1 n |
|
Figure 2.
In‐depth industrial‐scale proteomics. A portion of each of a set of carefully selected samples from patients with a disease is pooled, while separate portions are retained unpooled. Small squares represent an example of a protein common to all diseased samples, and the small triangle represents a protein present in one particular sample (phenotypic variation), prior to and after extensive separation. Identified/characterized proteins populate a database. Similar analysis of a control set permits comparisons to be made. The unpooled portions of the individual samples are used for screening for proteins of interest using arrays or other appropriate high‐throughput assays. |
|
Figure 3.
Donor sample‐based high‐throughput proteomics. A large set of small samples (here 10000) from patients with a disease is analyzed. Similar analysis of a control set permits comparisons to be made. |
References
Cahill DJ (2001) Protein and antibody arrays and their medical applications. Journal of Immunological Methods 250: 81–91.
Ezzel C (2002) Move over, human genome. Scientific American April: 42–47.
Graves PR and Haystead TAJ (2002) Molecular biologists's guide to proteomics. Microbiology and Molecular Biology Reviews 66: 39–63.
Lander ES, Linton LM, Birren B, et al. (2001) International human genome sequencing consortium: initial sequencing and analysis of the human genome. Nature 409: 860–921.
Mann M, Hendrickson RC and Pandey A (2001) Analysis of proteins and proteomes by mass spectrometry. Annual Review of Biochemistry 70: 437–473.
Venter JC, Adams MD, Myers EW, et al. (2001) The sequence of the human genome. Science 291: 1304–1351.
Zuo X and Speicher DW (2002) Comprehensive analysis of complex proteomes using microscale solution isoelectric focusing prior to narrow pH range two‐dimensional electrophoresis. Proteomics 2: 58–68.
Further Reading
Arrel DK and Van Eyk JE (2001) Cardiovascular proteomics, evolution and potential. Circulation Research 88: 763–773.
Ho Y, Gruhler A, Heilbut A et al. (2002) Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature 415: 180–183.
Kersten B, Bürkle L, Kuhn EJ, et al. (2002) Large‐scale plant proteomics. Plant Molecular Biology 48: 133–141.
Subramanian G, Adams MD, Venter JC and Broder S (2001) Implications of the human genome for understanding human biology and medicine. Journal of the American Medical Association 286: 2296–2307.
Weinstein JN (2001) Searching for pharmacogenomic markers: the synergy between omic and hypothesis‐driven research. Disease Markers 17: 77–88.
Web Links
Expert Protein Analysis System (ExPASy) http://www.expasy.ch
Human Proteome Organization (HUPO) http://www.hupo.org
Contact Editor 
Submit a note to the editor about this article by filling in the form below.
* Required Field
How to Cite
Rose, Keith(Jan 2006) Industrialization of Proteomics: Scaling UpProteomics Processes. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1038/npg.els.0006199]
